News | August 12, 2021
Indian pharma market grew by 13.7% in July 2021: Ind-Ra
Demand normalisation post the second wave contributed to the steady growth
Demand normalisation post the second wave contributed to the steady growth
It plays a pivotal role in monitoring pharmaceutical pricing
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The company is eligible for 12 months exclusivity from launch
The company has strong product launches both in India and overseas
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
The profits were bolstered by the Boehringer Ingelheim MEK program income
Subscribe To Our Newsletter & Stay Updated
